Skip to content

Nuvalent, Inc. NUVL Financing Cash Flow

Financing Cash Flow at other companies

Pfizer logo
PfizerPFE
-$2.86B+45.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$223.93M+22,903%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$3.8M-50.5%
Exelixis logo
ExelixisEXEL
-$457.11M-55.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$238.74M+27,216%
Incyte logo
IncyteINCY
$84.82M+769%

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s financing cash flow?
Nuvalent, Inc. (NUVL) reported financing cash flow of $9.8M in Q1 2026.
How has Nuvalent, Inc.'s financing cash flow changed year-over-year?
Nuvalent, Inc.'s financing cash flow increased by 115.5% year-over-year, from $4.55M to $9.8M.
What is the long-term trend for Nuvalent, Inc.'s financing cash flow?
Over 4 years (2021 to 2025), Nuvalent, Inc.'s financing cash flow has grown at a 12.7% compound annual growth rate (CAGR), from $319.17M to $515.34M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.